{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:34:08Z","timestamp":1793126048849,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003125","name":"Finnish Cultural Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107662","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:44:47Z","timestamp":1788795887000},"page":"107662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Novel inhibitors of BCRP found among drugs used in the treatment of cancer"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7860-0595","authenticated-orcid":false,"given":"Martina","family":"Timonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-8265","authenticated-orcid":false,"given":"Anne M.","family":"Filppula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Hirvensalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksi","family":"Tornio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-2189","authenticated-orcid":false,"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-6923","authenticated-orcid":false,"given":"Feng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107662_bib0002","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/B978-0-443-15274-0.50428-5","article-title":"Machine learning models for predicting membranolytic anticancer peptides","volume":"52","author":"Alimirzaei","year":"2023","journal-title":"Comput. Aided Chem. Eng."},{"issue":"9","key":"10.1016\/j.ejps.2026.107662_bib0003","doi-asserted-by":"crossref","first-page":"13848","DOI":"10.3390\/molecules190913848","article-title":"Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance","volume":"19","author":"Anreddy","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2026.107662_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110712","article-title":"Graphene aerogel nanoparticles for in-situ loading\/pH sensitive releasing anticancer drugs","volume":"186","author":"Ayazi","year":"2020","journal-title":"Colloids Surf., B Biointerfaces"},{"key":"10.1016\/j.ejps.2026.107662_bib0005","article-title":"Reduced polydopamine coated graphene for delivery of Hset1 antisense as A photothermal and gene therapy of breast cancer","volume":"73","author":"Babavalian","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"3\u20134","key":"10.1016\/j.ejps.2026.107662_bib0006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","article-title":"Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass","volume":"41","author":"Barpe","year":"2010","journal-title":"Eur. J. Pharm. Sci. : Off. J. Eur. Fed. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.119.257600","article-title":"Quantitative contribution of six major transporters to the hepatic uptake of drugs: \u201cSLC-Phenotyping\u201d using primary human hepatocytes","volume":"370","author":"Bi","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.ejps.2026.107662_bib0008","first-page":"1018","article-title":"Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling","volume":"10","author":"Costales","year":"2021","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2026.107662_bib0009","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bcpt.13928","article-title":"Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors","volume":"133","author":"Deng","year":"2023","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2026.107662_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106362","article-title":"Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs","volume":"181","author":"Deng","year":"2023","journal-title":"Eur. J. Pharm. Sci. : Off. J. Eur. Fed. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0011","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s11671-024-04086-6","article-title":"Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment","volume":"19","author":"Dhiman","year":"2024","journal-title":"Discov. Nano"},{"issue":"8","key":"10.1016\/j.ejps.2026.107662_bib0012","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"issue":"9","key":"10.1016\/j.ejps.2026.107662_bib0013","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acs.chemrestox.5c00225","article-title":"Inhibitory effects of alkaloids on BCRP implicated in reversing multidrug resistance: a case example of enhancing temozolomide cytotoxicity","volume":"38","author":"Duan","year":"2025","journal-title":"Chem. Res. Toxicol."},{"issue":"9","key":"10.1016\/j.ejps.2026.107662_bib0014","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","article-title":"Pharmacokinetic drug-drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer","volume":"59","author":"Duran","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib0016","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.115.066795","article-title":"Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure","volume":"44","author":"Elsby","year":"2016","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40262-022-01204-4","article-title":"Can mechanistic static models for drug-drug interactions support regulatory filing for study waivers and label recommendations?","volume":"62","author":"Gomez-Mantilla","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100036","article-title":"Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials","volume":"53","author":"Gu","year":"2025","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.ejps.2026.107662_bib0022","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.msec.2015.05.077","article-title":"Curcumin-reduced graphene oxide sheets and their effects on human breast cancer cells","volume":"55","author":"Hatamie","year":"2015","journal-title":"Mater. Sci. Eng., C Mater. Biol. Appl."},{"issue":"4","key":"10.1016\/j.ejps.2026.107662_bib0023","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0024","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12951-019-0519-6","article-title":"Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides","volume":"17","author":"Hong","year":"2019","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.ejps.2026.107662_bib0025","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/dmd.105.007534","article-title":"ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein","volume":"34","author":"Huang","year":"2006","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"issue":"17","key":"10.1016\/j.ejps.2026.107662_bib0027","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1021\/acs.jmedchem.5b01105","article-title":"An aggregation advisor for ligand discovery","volume":"58","author":"Irwin","year":"2015","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib66","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00552719","article-title":"Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia","volume":"14","author":"Jurlina","year":"1985","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9\u201310","key":"10.1016\/j.ejps.2026.107662_bib0029","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12272-025-01567-9","article-title":"Dual inhibitors of P-glycoprotein and breast cancer resistance protein for overcoming the blood-brain barrier: in silico discovery and preclinical evaluation","volume":"48","author":"Kang","year":"2025","journal-title":"Arch. Pharmacal Res."},{"issue":"7","key":"10.1016\/j.ejps.2026.107662_bib0031","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/bcp.15684","article-title":"Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: a breast cancer resistance protein-mediated drug interaction?","volume":"89","author":"Lehtisalo","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0032","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cpt.3067","article-title":"Ticagrelor increases exposure to the breast cancer resistance protein substrate rosuvastatin","volume":"115","author":"Lehtisalo","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejps.2026.107662_bib0033","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70271","article-title":"Using pharmacovigilance data for signal detection of drug interactions for rosuvastatin","volume":"139","author":"Levom\u00e4ki","year":"2026","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0034","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2013an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"issue":"10","key":"10.1016\/j.ejps.2026.107662_bib0035","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","article-title":"Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin. Ther."},{"issue":"11","key":"10.1016\/j.ejps.2026.107662_bib0036","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1023\/A:1013180903805","article-title":"Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors","volume":"12","author":"Marty","year":"2001","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ejps.2026.107662_bib0037","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","article-title":"Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs","volume":"26","author":"Matsson","year":"2009","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejps.2026.107662_bib0038","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.coph.2013.08.010","article-title":"Clinical relevance of drug efflux pumps in the gut","volume":"13","author":"Misaka","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0039","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1087057116657513","article-title":"Virtual screening of DrugBank reveals two drugs as new BCRP inhibitors","volume":"22","author":"Montanari","year":"2017","journal-title":"SLAS Discov. : Adv. Life Sci. R & D"},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/genes16030248","article-title":"The association between statin drugs and rhabdomyolysis: an analysis of FDA adverse event reporting system (FAERS) data and transcriptomic profiles","volume":"16","author":"Morris","year":"2025","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0041","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/1078155220923001","article-title":"Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: a case report and review of the literature","volume":"27","author":"Ould-Nana","year":"2021","journal-title":"J. Oncol. Pharm. Pract. : Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.ejps.2026.107662_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2026.100312","article-title":"Advances in organ-on-chip for drug transporter study: key insights and hurdles","volume":"54","author":"Petit","year":"2026","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.acuro.2025.501689","article-title":"Abiraterone and rosuvastatin-induced rhabdomyolysis","volume":"49","author":"Porto Fuentes","year":"2025","journal-title":"Actas Urol. Esp."},{"issue":"12","key":"10.1016\/j.ejps.2026.107662_bib0045","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1021\/acsbiomaterials.2c00531","article-title":"Engineered biomimetic membranes for organ-on-a-chip","volume":"8","author":"Rahimnejad","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"6","key":"10.1016\/j.ejps.2026.107662_bib0046","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-06-0811","article-title":"Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure","volume":"6","author":"Robey","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.ejps.2026.107662_bib0047","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"In silico\u201d simulations to assess the \u201cin vivo\u201d consequences of \u201cin vitro\u201d metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov. Today, Technol."},{"issue":"4","key":"10.1016\/j.ejps.2026.107662_bib0048","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-024-04683-3","article-title":"Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : brief title: drug-drug interaction of midostaurin","volume":"94","author":"Sechaud","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0049","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/agm2.12051","article-title":"Polypharmacy in elderly cancer patients: challenges and the way clinical pharmacists can contribute in resource-limited settings","volume":"2","author":"Shrestha","year":"2019","journal-title":"Aging Med. (Milton (N.S.W))"},{"issue":"5","key":"10.1016\/j.ejps.2026.107662_bib0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2165\/00003495-200868050-00005","article-title":"Temsirolimus: in advanced renal cell carcinoma","volume":"68","author":"Simpson","year":"2008","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib0051","first-page":"269","article-title":"Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide","volume":"69","author":"Stewart","year":"1985","journal-title":"Cancer Treat. Rep."},{"issue":"9\u201310","key":"10.1016\/j.ejps.2026.107662_bib0052","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","article-title":"The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)","volume":"13","author":"Szak\u00e1cs","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2026.107662_bib0053","doi-asserted-by":"crossref","DOI":"10.1038\/srep41376","article-title":"Interactions of retinoids with the ABC transporters P-glycoprotein and breast cancer resistance protein","volume":"7","author":"Tarapcs\u00e1k","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib0054","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cpt.2670","article-title":"Clinical relevance of hepatic and renal P-gp\/BCRP inhibition of drugs: an international transporter consortium perspective","volume":"112","author":"Taskar","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ejps.2026.107662_bib0055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s12020-014-0517-2","article-title":"Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro","volume":"49","author":"Theile","year":"2015","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0056","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-024-01457-1","article-title":"Static versus dynamic model predictions of competitive inhibitory metabolic drug-drug interactions via cytochromes P450: one step forward and two steps backwards","volume":"64","author":"Tiryannik","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2026.107662_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114061","article-title":"Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme","volume":"178","author":"Vagiannis","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2026.107662_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100056","article-title":"Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions","volume":"53","author":"West","year":"2025","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2026.107662_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.08.021","article-title":"Effect of excipients on breast cancer resistance protein substrate uptake activity","volume":"124","author":"Yamagata","year":"2007","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.ejps.2026.107662_bib0061","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/cts.12750","article-title":"In Vitro-to-In vivo extrapolation of transporter inhibition data for drugs approved by the US food and drug administration in 2018","volume":"13","author":"Yu","year":"2020","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107662_bib0062","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/dmd.116.073411","article-title":"What can be learned from recent new drug applications? A systematic review of drug interaction data for drugs approved by the US FDA in 2015","volume":"45","author":"Yu","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.ejps.2026.107662_bib0063","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.108.023648","article-title":"Relationship between drug\/metabolite exposure and impairment of excretory transport function","volume":"37","author":"Zamek-Gliszczynski","year":"2009","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.ejps.2026.107662_bib0064","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.phrs.2017.01.024","article-title":"Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib","volume":"119","author":"Zhang","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2026.107662_bib0065","first-page":"1","article-title":"Comparative lipid-lowering\/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials","volume":"2020","author":"Zhang","year":"2020","journal-title":"Cardiovasc. Ther."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:55:38Z","timestamp":1793123738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726002368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":57,"alternative-id":["S0928098726002368"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107662","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel inhibitors of BCRP found among drugs used in the treatment of cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107662"}}